✦ LIBER ✦

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

✍ Scribed by Thorsten Braun; Pierre Fenaux

Book ID: 108675714
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 196 KB
Volume: 141
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2008.07099.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mammalian target of rapamycin inhibitors

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

✍ David T. Teachey; Stephan A. Grupp; Valerie I. Brown 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

The route to development of myelodysplas

The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies

✍ Emanuela Maserati; Barbara Pressato; Roberto Valli; Antonella Minelli; Laura Sai 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Serial determination of FLT3 mutations i

Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance

✍ Georgios Georgiou; Vasiliki Karali; Christina Zouvelou; Elias Kyriakou; Maria Di 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Maintenance treatment with azacytidine f

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

✍ Michael Grövdal; Mohsen Karimi; Rasheed Khan; Anni Aggerholm; Petar Antunovic; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

Platelet doubling after the first azacit

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

✍ Lieke H. van der Helm; Canan Alhan; Pierre W. Wijermans; Marinus van Marwijk Koo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB